Last reviewed · How we verify
CKD-701
CKD-701 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
CKD-701 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers. Used for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
At a glance
| Generic name | CKD-701 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | Selective Estrogen Receptor Degrader (SERD) |
| Target | Estrogen Receptor (ER) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CKD-701 functions as a SERD by binding to the estrogen receptor with high affinity and promoting its proteasomal degradation, thereby eliminating both ligand-dependent and ligand-independent estrogen receptor signaling. This mechanism differs from selective estrogen receptor modulators (SERMs) by achieving complete receptor elimination rather than modulation. The drug is designed to overcome resistance to tamoxifen and aromatase inhibitors in hormone receptor-positive breast cancer.
Approved indications
- Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
Common side effects
- Hot flashes
- Nausea
- Fatigue
- Vaginal bleeding or discharge
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-701 CI brief — competitive landscape report
- CKD-701 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI